MedTrace Logo

Biocollection in MyeloDysplastic Syndrome (P-MDS)

NCT04869683 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-02-05

No results posted yet for this study

Summary

Myelodysplastic syndromes (MDS) are chronic myeloid hemopathies characterized by ineffective hematopoiesis (with peripheral cytopenias) and which contrast with a marrow of normal richness. MDS is considered one of the four most common blood diseases. The incidence is estimated at 4,059 cases / year in 2012 with an average age of 78 years in men and 81 years in women (INCA report, Cancers in France in 2015). The incidence increases with lengthening of the lifespan. The main risk of MDS is transformation to acute leukemia in 30 to 40% of cases. Treatment options depend on clinical, hematologic and chromosomal abnormalities. The prognosis is considered to be at low or high risk of developing acute leukemia. This distinction will therefore have an impact on the therapeutic solution (s). MDS exhibit clinical, morphological and genetic heterogeneity. It is therefore necessary to form subgroups of patients to better understand the physiopathogenesis of this pathology. The constitution of a biocollection will make it possible to search for clinical and biological prognostic markers in order to identify patients progressing to acute myeloid leukemia.

Conditions

  • Myelodysplastic Syndromes
  • Myelodysplastic Anemia
  • Myelodysplastic Syndrome With Isolated Del(5Q)
  • Myelodysplastic Syndrome With Ring Sideroblasts
  • Acute Myeloid Leukemia With Multilineage Dysplasia
  • Chromosome Abnormality

Interventions

OTHER

description of MDS pzatient cohort

description of MDS patient cohort

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Principal Investigators

  • Nathalie Douet-Guilbert, MD,PhD · CHRU Brest

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-19
Primary Completion
2032-10-19
Completion
2032-10-19

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04869683 on ClinicalTrials.gov